

## DIVI'S LABORATORIES LIMITED

### UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>TH</sup> JUNE, 2007

(Rs.in Lakhs)

	Particulars	STAND ALONE			CONSOLIDATED		
		Unaudited	Unaudited	Audited	Unaudited	Unaudited	Audited
		Quarter ended 30.06.2007	Quarter Ended 30.06.2006	Year Ended 31.03.2007	Quarter ended 30.06.2007	Quarter Ended 30.06.2006	Year Ended 31.03.2007
(1)	(2)	(3)	(4)	(5)	(6)	(7)	
1	Net Sales/Income from operations (net of Excise Duty)	<b>22807</b>	16084	72442	<b>22672</b>	16069	72458
2	Other Income	<b>344</b>	436	1361	<b>339</b>	434	1343
3	<b>Total Income:</b>	<b>23151</b>	16520	73803	<b>23011</b>	16503	73801
4	<b>Expenditure:</b>						
	a. (Increase) / Decrease in Stock	<b>(623)</b>	437	1198	<b>(680)</b>	370	1056
	b. Consumption of Raw Material	<b>10713</b>	7758	31112	<b>10658</b>	7794	31253
	c. Staff Cost	<b>1148</b>	964	5158	<b>1235</b>	1040	5511
	d. Other Expenditure						
	- Manufacturing Expenses	<b>1416</b>	934	4381	<b>1417</b>	951	4392
	- Other expenses	<b>1727</b>	1384	5994	<b>1813</b>	1447	6372
5	Finance charges	<b>337</b>	206	1057	<b>337</b>	206	1058
6	Depreciation	<b>861</b>	426	2233	<b>862</b>	427	2235
7	<b>Total Expenses:</b>	<b>15579</b>	12109	51133	<b>15641</b>	12235	51877
8	<b>Profit Before Tax (3-7)</b>	<b>7572</b>	4411	22670	<b>7370</b>	4267	21924
	Provision for Taxation						
9	- Current Tax	<b>485</b>	1670	3332	<b>485</b>	1670	3333
	- Deferred Tax	<b>355</b>	63	137	<b>391</b>	31	-22
	- Fringe Benefit Tax	<b>4</b>	3	27	<b>4</b>	3	27
10	<b>Net Profit: (8-9)</b>	<b>6728</b>	2675	19174	<b>6490</b>	2563	18586
11	Paid-up Equity Share Capital	<b>1291</b>	1282	1291	<b>1291</b>	1282	1291
12	Reserves excluding revaluation reserves			52913			52250
13	Basic Earnings Per Share Rs.	<b>52.11</b>	20.86	149.54	<b>50.27</b>	20.00	144.95
	Diluted Earnings Per Share Rs. (Face Value : Rs.10 per share)	<b>51.85</b>	20.47	147.77	<b>50.02</b>	19.62	143.24
14	Aggregate of public shareholding:						
	- No. of shares	<b>5998520</b>	5903200	5998420	<b>5998520</b>	5903200	5998420
	- % of shareholding	<b>46.46%</b>	46.05%	46.46%	<b>46.46%</b>	46.05%	46.46%

## NOTES:

1. The above results for the Quarter ended 30<sup>th</sup> June 2007, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 30<sup>th</sup> July, 2007.
2. The Consolidated results include the un-audited results of the subsidiaries, Divis Laboratories (USA) Inc., and Divi's Laboratories Europe AG.
3. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 on Segment Reporting issued by the Institute of Chartered Accountants of India.
4. The company has charged an amount of Rs.226 lakhs during the current quarter towards Employee Compensation Expense on account of the outstanding stock options granted to eligible employees.
5. The figures for the previous year/period have been regrouped, wherever necessary.
6. Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 30.06.2007:  
Opening: Nil, Received during the Quarter: 16, Resolved: 16, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad  
Date: 30<sup>th</sup> July, 2007

Dr. Murali K. Divi  
Chairman & Managing Director